An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy
February 3, 2015 updated by: Frank Lippert
The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect.
Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.
Study Overview
Status
Completed
Conditions
Detailed Description
The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies.
While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs.
This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT).
The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area.
After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture.
During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period.
Fluoride free toothpaste will be used two to three days before and continuously during each treatment period.
After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test.
Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable.
Each subject (n = 28) will serve as his or her own control.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Oral Health Research Institute, Indiana University School of Dentistry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
- be between 18 and 80 years old and in general good health;
- willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
- wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
- be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
- be in good dental health with no active caries or periodontal disease;
- agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
- Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening
Exclusion Criteria:
be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.
- have any medical condition that could be expected to interfere with the subject's safety during the study period;
- demonstrate an inability to comply with study procedures;
- have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
- be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
- be lactose intolerant or have known allergy or intolerance to milk or milk products
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
|
|
Other: Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
|
|
Other: Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
|
|
Other: Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
|
|
Active Comparator: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
Time Frame: Three Weeks per each of five arms
|
|
Three Weeks per each of five arms
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% Acid Resistance Score Per Each of Five Arms
Time Frame: Three Weeks per each of five arms
|
% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
|
Three Weeks per each of five arms
|
|
Enamel Fluoride Uptake Per Each of Five Arms
Time Frame: Three Weeks per each of five arms
|
Enamel fluoride uptake is a measure of fluoridation of a caries lesion
|
Three Weeks per each of five arms
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Domenick Zero, DDS, MS, Indiana University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
August 7, 2012
First Submitted That Met QC Criteria
August 13, 2012
First Posted (Estimate)
August 16, 2012
Study Record Updates
Last Update Posted (Estimate)
February 23, 2015
Last Update Submitted That Met QC Criteria
February 3, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-I-086
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Caries
-
Hue University of Medicine and PharmacyRecruitingOcclusal Caries | Caries,Dental | Caries; InitialVietnam
-
Ain Shams UniversityCompletedPulpitis | Caries | Caries,Dental | Reversible Pulpitis | Caries Class I | Caries; DentinEgypt
-
Hacettepe UniversityRecruitingDeep Caries | Dentin CariesTurkey
-
University of MinnesotaCompletedUsing Motivational Interviewing To Reduce Parental Risk-Related Behaviors For Early Childhood CariesCaries | Caries,DentalUnited States
-
Cairo UniversityNot yet recruitingPit and Fissure Caries | Caries; InitialEgypt
-
Rawda Hesham Abd ElAzizRecruitingCaries,Dental | Caries Class IIEgypt
-
National University of San Marcos, PeruNot yet recruitingPit and Fissure Caries | Caries,Dental | Sealant DentalPeru
-
Western University, CanadaUnknownCaries,Dental | Caries Arrested
-
Ain Shams UniversityRecruiting
-
CareQuest Institute for Oral HealthActive, not recruitingDental Caries in Children | Dental Caries | Initial Caries | Arrested Dental Caries | Cavitated CariesUnited States
Clinical Trials on 1.5 mg Sodium Fluoride in 100 ml milk
-
Novartis PharmaceuticalsRecruitingPrimary Prevention of Atherosclerotic Cardiovascular DiseaseUnited States, China, Italy, Spain, Canada, France, Netherlands, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South Africa and more
-
PfizerCompleted
-
Shanghai Henlius BiotechActive, not recruiting
-
PT BernofarmPT Pharma Metric LabsCompleted
-
Shanghai Henlius BiotechActive, not recruitingMetastatic Colorectal Cancer (mCRC)China
-
National Cardiovascular Center Harapan Kita Hospital...CompletedChronic Kidney Disease | Cardiac DiseaseIndonesia
-
dr. P. NoordzijPharmacosmos A/SRecruitingIron Deficiency AnemiaNetherlands
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)WithdrawnUpper Respiratory Infections
-
Taiwan Liposome CompanyCompletedOsteoarthritis of the KneeTaiwan, Australia
-
IRCCS San Raffaele RomaRecruitingMigraine DisordersItaly